OMCL
Omnicell, Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP EBITDA non-GAAP | $45M | Q1 2026 | — |
|
|
|||
| Product bookings | $535M | year ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OMCL
this stock
Omnicell, Inc.
|
$2.04B | -0.8% | +10.5% | 102.1 | 7.0% |
|
VEEV
Veeva Systems Inc
|
$30.88B | -14.8% | +28.1% | 33.7 | 4.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$15.67B | -9.4% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$13.85B | +90.7% | -0.4% | 51.0 | 6.6% |
|
TEM
Tempus AI, Inc.
|
$10.46B | -1.4% | +65.8% | — | 18.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OMCL | +4.4% | +17.5% | -11.9% | +8.2% | -0.8% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +3.0% | +13.4% | -21.0% | +7.1% | -11.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.